drugset / Trial / NCT01820715

A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain

NCT01820715

Phase 1 Completed 31 enrolled Dong-A Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for Neuropathic pain.

Timeline

Start
2010-06
Primary completion
2013-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucostim Unknown 600 ug

Indications